<?xml version="1.0" ?>
<GlossaryTerm id="CDR0000045060">
  <TermName>halofuginone hydrobromide</TermName>
  <TermPronunciation>(HA-loh-FYOO-jih-none HY-droh-BROH-mide)</TermPronunciation>
  <TermDefinition>
    <DefinitionText>A substance that is being studied for its ability to slow the growth of connective tissue and to prevent the growth of new blood vessels that tumors need to grow. It is a type of quinazolinone alkaloid and a type of antiangiogenesis agent.</DefinitionText>
    <Dictionary>Cancer.gov</Dictionary>
    <Audience>Patient</Audience>
  </TermDefinition>
  <MediaLink ref="CDR0000727458" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;halofuginone hydrobromide&quot;" language="en" id="_3"/>
  <MediaLink ref="CDR0000727457" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;bromhidrato de halofuginona&quot;" language="es" id="_4"/>
  <SpanishTermName>bromhidrato de halofuginona</SpanishTermName>
  <SpanishTermDefinition>
    <DefinitionText>Sustancia en estudio por su capacidad de retrasar el crecimiento del tejido conjuntivo e impedir el crecimiento de  vasos sanguíneos nuevos que los tumores necesitan para crecer. Es un tipo de alcaloide de quinazolinona y de antiangiogénico.</DefinitionText>
    <Dictionary>Cancer.gov</Dictionary>
    <Audience>Patient</Audience>
  </SpanishTermDefinition>
  <DateLastModified>2009-04-21</DateLastModified>
</GlossaryTerm>
